Given the direct correlation between synaptic plasticity and cognitive impairment in AD, therapeutic strategies built on “ACSS2/histone acetylation/glutamate receptor” will provide novel perspectives for the treatment of AD. This evidence concerns the gene ACSS2 and Alzheimer disease.